Hepatocellular carcinoma-cause, treatment and metastasis

World Journal of Gastroenterology

Volumn 7, Issue 4, 2001, Pages 445-454

  Tang, Z Y ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; AFLATOXIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BATIMASTAT; BIOLOGICAL MARKER; CARMOFUR; CISPLATIN; CYTOKINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; IODINATED POPPYSEED OIL; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; OCTREOTIDE; PACLITAXEL; POLYPRENOIC ACID; RETINOIC ACID; SOMATOSTATIN DERIVATIVE; SYNTHETIC PEPTIDE; TAC 101; TAMOXIFEN; TUMOR VACCINE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

BIOLOGICAL THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIETARY INTAKE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; GENE THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG SMALL CELL CANCER; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; POPULATION RESEARCH; REVIEW; TUMOR RECURRENCE;

EID: 0034893404     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i4.445     Document Type: Review

References (192)

1. Estimates of the worldwide mortality from 25 cancers in 1990
2. Increase in primary liver cancer in the UK, 1979-1994
3. Rising incidence of hepatocellular carcinoma in the United States
4. Cancer statistics, 1998
5. Cancer survival in Shanghai, People's Republic of China
6. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China
7. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: A prospective study
8. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
9. Hepatitis C virus 1b (II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: A case-control study in Japan
10. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study
11. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis
12. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice
13. Does hepatitis GB virus-C infection cause hepatocellular carcinoma in black Africans?
14. GB virus-C RNA in Japanese patients with hepatocellular carcinoma and cirrhosis
15. GB virus C/ hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China
16. Hepatitis G infection: Role in cryptogenic chronic liver disease and primary liver cell cancer in the UK. Trent Hepatitis C virus Study Group
17. In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions
18. A case-control study on a novel DNA virus (TT virus) infection and hepatocellular carcinoma. The Brescia HCC Study
19. A case-control study on GB virus C/ hepatitis G virus infection and hepatocellular carcinoma. Brescia HCC Study
20. Chronic infection with hepatitis C virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles County, California
21. High prevalence of transfusion-transmitted virus among patients with non-B, non-C hepatocellular carcinoma
22. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1
23. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma
24. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan
25. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC Study
26. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans
27. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study
28. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan
29. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice
30. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein
31. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas
32. Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells
33. Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1
34. Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis
35. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
36. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan
37. Primary prevention of hepatocellular carcinoma
38. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: A multivariate analysis in 343 patients
39. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study
40. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
41. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhosis, fibrosis, or nonfibrosis
42. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy
43. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
44. Hepatocellular carcinoma
45. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma
46. Early hepatocellular carcinoma as an entity with a high rate of surgical cure
47. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience
48. Hepatic resection for hepatocellular carcinoma - Japanese experience
49. Progress and prospects in hepatocellular carcinoma surgery
50. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma
51. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection
52. Partial hepatectomy accelerates local tumor growth: Potential roles of local cytokine activation
53. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma
54. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma-evaluation with analysis of 72 patients
55. Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome
56. Should hepatomas be treated with hepatic resection or transplantation?
57. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
58. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: A retrospective analysis
59. Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma
60. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective
61. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
62. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
63. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
64. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC
65. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma
66. Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma
67. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: Comparison of planned periodic chemoembolization and chemoembolization based on tumor response
68. Transarterial chemoembolization for hepatocellular carcinoma: Volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center
69. Complications associated with transcatheter arterial embolization for hepatic tumors
70. Percutaneous ethanol injection therapy in 47 cirrhotic patients with hepatocellular carcinoma 5 cm or less: A long-term result
71. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection
72. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma
73. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma
74. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: Comparison with percutaneous ethanol injection therapy
75. Percutaneous microwave coagulation therapy for hepatocellular carcinoma located on the surface of the liver
76. Sonographically guided microwave coagulation treatment of liver cancer: An experimental and clinical study
77. Clinical results of radiofrequency hyperthermia for malignant liver tumors
78. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection
79. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma
80. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres
81. 131I-anti-HCC mAb. Phase I / II clinical trials
82. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
83. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
84. Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines
85. Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/ uracil
86. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study
87. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients
88. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma
89. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study
90. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial
91. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)
92. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
93. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
94. Gene therapy for hepatocellular carcinoma-progress but many stones yet unturned
95. Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice
96. Retrovirus-mediated gene therapy for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter
97. Hepatoma-specific gene therapy through retrovirus-mediated and targeted gene transfer using an adenovirus carrying the ecotropic receptor gene
98. Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer
99. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene
100. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation
101. The targeted expression of the human interleukin-2 interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells
102. p53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
103. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: Limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy
104. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer
105. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
106. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
107. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo
108. Expression of MAGE genes and survival in patients with hepatocellular carcinoma
109. High frequency of expression of MAGE genes in human hepatocellular carcinoma
110. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma
111. Expression of the MAGE gene family in human hepatocellular carcinoma
112. MAGE-1 and related MAGE gene expression may be associated with hepatocellular carcinoma
113. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice
114. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients
115. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma
116. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance
117. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence
118. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation
119. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma
120. Quantitation of telomerase activity in hepatocellular carcinoma: A possible aid for a prediction of recurrent diseases in the remnant liver
121. Preoperative chemoembolization of hepatocellular carcinoma: A comparative study
122. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection
123. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma - Results of long-term follow-up
124. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis
125. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma
126. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study
127. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial
128. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group
129. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma
130. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
131. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma
132. Amplification of c-myc in hepatocellular carcinoma: Correlation with clinicopathologic features, proliferative activity and p53 overexpression
133. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma
134. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma
135. Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas
136. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma
137. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells
138. Integrin alpha-6-beta1 plays a significant role in the attachment of hepatoma cells to laminin
139. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis
140. Clinical implications of telomerase activity in resected hepatocellular carcinoma
141. The role of telomerase activity in hepatocellular carcinoma
142. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma
143. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma
144. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma
145. Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells
146. Significance of nm23 mRNA expression in human hepatocellular carcinoma
147. Overexpression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma
148. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma
149. Differential expression of laminin receptors in human hepatocellular carcinoma
150. Transforming growth factor a induces proliferation and expression of epidermal growth factor receptor in hepatocellular carcinoma cells
151. p53 mutations may be related to tumor invasiveness of human hepatocellular carcinoma in China
152. mRNA levels of nm23 in murine ascites hepatoma (H22) clones with different lymphatic metastatic potential
153. Alterations of CDKN2 (P16/MTS1) exon 2 in human hepatocellular carcinoma
154. Expression of the integrin a5 subunit and its mediated cell adhesion in hepatocellular carcinoma
155. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma
156. Kai-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases
157. The abundance of NM23-H1 mRNA is related with insitu microenvironment and intrahepatic metastasis in hepatocellular carcinoma
158. Invasion and metastasis of liver cancer: Expression of intercellular adhesion molecule 1
159. N-Actylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice
160. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor
161. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: With relation to tumor size and invasiveness
162. Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis
163. Surgery of hepatocellular carcinoma with special reference to studies on metastasis and recurrence
164. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma
165. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma
166. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-homologous to rat RhoGAP)
167. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues
168. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis
169. Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice
170. Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes
171. Establishment of a lymph node metastatic model of mouse hepatocellular carcinoma Hca-F cells in C3H/Hej mice
172. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma
173. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma
174. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma
175. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma
176. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
177. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma
178. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma
179. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus
180. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
181. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: Its clinical and prognostic significance
182. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry
183. Microvessel density of hepatocellular carcinoma: Its relationship with prognosis
184. Vascularization of small hepatocellular carcinomas: Correlation with differentiation
185. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma
186. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats
187. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential
188. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20
189. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals
190. Modulation of apoptosis, tumorigenicity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20
191. Inhibitory effects of synthetic β peptide on invasion and metastasis of liver cancer